JM Gatell

829 total citations
15 papers, 410 citations indexed

About

JM Gatell is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, JM Gatell has authored 15 papers receiving a total of 410 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 9 papers in Virology and 4 papers in Emergency Medicine. Recurrent topics in JM Gatell's work include HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (9 papers) and HIV-related health complications and treatments (4 papers). JM Gatell is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), HIV Research and Treatment (9 papers) and HIV-related health complications and treatments (4 papers). JM Gatell collaborates with scholars based in Spain, United States and United Kingdom. JM Gatell's co-authors include Estebán Martínez, Felipe García, Ana Milinkovic, Glòria Garrabou, F Cardellach, Tomàs Pumarola, Sònia López, Enric Pedrol, Óscar Miró and Elisabet Deig and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Virology and European Respiratory Journal.

In The Last Decade

JM Gatell

15 papers receiving 394 citations

Peers

JM Gatell

EPIDE

VIROL

IMMUN

María Mercedes Castrejón Panama

Opass Putcharoen Thailand

Melchor Riera Spain

M. Farley United States

S. Forlenza United States

Natascia Sala Italy

Laurence Maulin France

Pilar Vizcarra Spain

Henry Luzze Uganda

Emilio Ledesma Belgium

María Mercedes Castrejón Panama

JM Gatell

213 ×0.9

129 ×0.7

EPIDE

131 ×0.8

VIROL

65 ×0.5

12 ×0.4

IMMUN

Citations per year, relative to JM Gatell JM Gatell (= 1×) peers María Mercedes Castrejón

Countries citing papers authored by JM Gatell

Since Specialization

Citations

This map shows the geographic impact of JM Gatell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JM Gatell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JM Gatell more than expected).

Fields of papers citing papers by JM Gatell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JM Gatell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JM Gatell. The network helps show where JM Gatell may publish in the future.

Co-authorship network of co-authors of JM Gatell

This figure shows the co-authorship network connecting the top 25 collaborators of JM Gatell. A scholar is included among the top collaborators of JM Gatell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JM Gatell. JM Gatell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Ferrer‐Márquez, Manuel, et al.. (2017). Fe de errores: Polifarmacia e interacciones farmacológicas potenciales en una población envejecida con infección por el VIH. Farmacia Hospitalaria. 41(6). 700–700. 1 indexed citations

Mocroft, Amanda, Lene Ryom, Hansjakob Furrer, et al.. (2015). Kidney disease in antiretroviral‐naïve HIV‐positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Medicine. 16(S1). 55–63. 24 indexed citations

Pérez, Isidro Sanz, et al.. (2012). Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study. Journal of Antimicrobial Chemotherapy. 68(2). 404–408. 12 indexed citations

Masiá, Mar, Estebán Martínez, Sergio Padilla, JM Gatell, & Félix Gutiérrez. (2012). Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study. Journal of Antimicrobial Chemotherapy. 68(2). 409–413. 16 indexed citations

Martínez, Estebán, Ma Ángeles Marcos, Andrés Antón, et al.. (2011). Influenza A H1N1 in HIV-infected adults*. HIV Medicine. 12(4). 236–245. 26 indexed citations

Medina-Ramírez, Max, Víctor Sánchez-Merino, Sonsoles Sánchez‐Palomino, et al.. (2011). Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia. Journal of Virology. 85(12). 5804–5813. 35 indexed citations

González, Raquel, Pedro Castro, Felipe García, et al.. (2010). Effects of highly active antiretroviral therapy on vaccine‐induced humoral immunity in HIV‐infected adults. HIV Medicine. 11(8). 535–539. 6 indexed citations

Lazzari, Elisa de, Agathe León, Estebán Martínez, et al.. (2008). Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts^*. HIV Medicine. 9(4). 221–226. 41 indexed citations

Mallolas, Josep, Daniel Podzamczer, Peré Domingo, et al.. (2008). Efficacy and safety of switching from lopinavir/r to atazanavir/r in suppressed patients receiving a LPV/r-containing HAART: ATAZIP 96-week results. Journal of the International AIDS Society. 11(Suppl 1). P53–P53. 1 indexed citations

10.

Mallolas, Josep, M. Arraiza, Meritxell Nomdedéu, et al.. (2007). Pharmacokinetic interaction between rifampicin and ritonavir‐boosted atazanavir in HIV‐infected patients^*. HIV Medicine. 8(2). 131–134. 24 indexed citations

11.

Gatell, JM, Dominique Salmon‐Céron, Adriano Lazzarin, et al.. (2005). Efficacy and Safety of atazanavir (ATV) Based HAART in patients switched from a stable boosted/unboosted protease-inhibitor (PI) treatment. The SWAN study. 3 indexed citations

12.

Gatell, JM, Dominique Salmon‐Céron, Adriano Lazzarin, et al.. (2005). Efficacy of atazanavir (ATV) based HAART in patients switched from a stable PI or boosted PI (PI/r) treatment. Planned week 24 analysis of a phase IIIb 48 week multicenter, open-label, randomized, prospective trial. The SWAN study. 2 indexed citations

13.

Miró, Óscar, Sònia López, Estebán Martínez, et al.. (2004). Mitochondrial Effects of HIV Infection on the Peripheral Blood Mononuclear Cells of HIV-Infected Patients Who Were Never Treated with Antiretrovirals. Clinical Infectious Diseases. 39(5). 710–716. 122 indexed citations

14.

Horcajada, Juan Pablo, Tomàs Pumarola, José Antonio Martínez, et al.. (2003). A nosocomial outbreak of influenza during a period without influenza epidemic activity. European Respiratory Journal. 21(2). 303–307. 95 indexed citations

15.

Kahn, Jeffrey P., Hammer Sm, David Katzenstein, et al.. (1997). Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.. PubMed. 2(4). 237–47. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact